CO6180496A2 - Composiciones liquidas de fenilefrina de estabilidad mejorada - Google Patents

Composiciones liquidas de fenilefrina de estabilidad mejorada

Info

Publication number
CO6180496A2
CO6180496A2 CO09002495A CO09002495A CO6180496A2 CO 6180496 A2 CO6180496 A2 CO 6180496A2 CO 09002495 A CO09002495 A CO 09002495A CO 09002495 A CO09002495 A CO 09002495A CO 6180496 A2 CO6180496 A2 CO 6180496A2
Authority
CO
Colombia
Prior art keywords
aldehyde
composition
polyethylene glycol
acid derivatives
aldehyde content
Prior art date
Application number
CO09002495A
Other languages
English (en)
Inventor
William Bubnis
Stephanie Shield
Gayle Hoskovec
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38814551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6180496(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO6180496A2 publication Critical patent/CO6180496A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una composición farmacéutica líquida oral que comprende:(a) fenilefrina o una sal farmacéuticamente aceptable de esta; y (b) polietilenglicol sustancialmente libre de aldehído, en donde el polietilenglicol sustancialmente libre de aldehído tiene menos de 20 ppm de contenido total de aldehído y mantiene dicho nivel de contenido de aldehído durante al menos seis meses. 2.- La composición de la reivindicación 1, en donde el polietilenglicol sustancialmente libre de aldehído tiene menos de 10 ppm de contenido total de aldehído y mantiene dicho nivel de contenido de aldehído durante al menos un año. 3.- La composición de la reivindicación 1 o reivindicación 2, comprende adicionalmente al menos un segundo agente activo seleccionado del grupo que consiste de agentes analgésicos, descongestionantes, expectorantes, anti-tusivos, antipiréticos, anti-inflamatorios, supresores de tos y antihistaminas. 4.- La composición de la reivindicación 3, en donde el segundo agente activo se selecciona del grupo que consiste de drogas anti-inflamatorias no esteroides (NSAIDS), derivados de ácido propiónico, ibuprofeno, naproxeno, cetoprofen, flurbiprofen, zomepirac, sulindac fenoprofen, suprofen, fluprofen, fenbufen; derivados de ácido acético, tolmetin sódico, indometacin, derivados de ácido fenámico, meclofenamato de sodio de ácido mefenámico, derivados de ácido bifenil carboxílico, diflunisal, flufenisal, oxicamos, piroxicam, sudoxicam, isoxicam, clorfeniramina, bromfeniramina; dexclorfeniramina, dexbromfeniramina, triprolidina, clorciclizina, difenhidramina, doxilamina, tripelenamina, ciproheptatina, bromodifenhidramina, fenindamina, pirilamina, azatadina, acrivastina, astemizol, azelastina, cetirizina, ebastina, fexofenadina, ketotifen, carbinoxamina, desloratadina, loratadina, feniramina, tonzilamina, mizolastina, terfenadina, clofendianol, caramifen, dextrometorfan, difenhidramina, codeina, hidrocodona, pseudoefedrina, efedrina, fenilefrina, fenilpropenolamina, hidrato de terpin, guaifenesina, potasio, guaicolsulfonato de potaio, inhibidores 2 Cox, Celecoxib, Rofecoxib, Valdecoxib, aspirina, acetaminofén, fenacetin, sales de salicilatos y combinaciones de estos.
CO09002495A 2006-07-14 2009-01-14 Composiciones liquidas de fenilefrina de estabilidad mejorada CO6180496A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/487,120 US20080014274A1 (en) 2006-07-14 2006-07-14 Enhanced stability phenylephrine liquid compositions

Publications (1)

Publication Number Publication Date
CO6180496A2 true CO6180496A2 (es) 2010-07-19

Family

ID=38814551

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09002495A CO6180496A2 (es) 2006-07-14 2009-01-14 Composiciones liquidas de fenilefrina de estabilidad mejorada

Country Status (26)

Country Link
US (1) US20080014274A1 (es)
EP (2) EP2351554B1 (es)
JP (1) JP2009543777A (es)
KR (2) KR20090040334A (es)
CN (2) CN104546671A (es)
AR (1) AR061985A1 (es)
AU (1) AU2007272961B2 (es)
BR (1) BRPI0714399B8 (es)
CA (1) CA2657611A1 (es)
CO (1) CO6180496A2 (es)
EC (1) ECSP099072A (es)
ES (2) ES2550036T3 (es)
HK (2) HK1128886A1 (es)
HU (2) HUE025790T2 (es)
IL (1) IL196447A (es)
MX (1) MX2009000530A (es)
NZ (1) NZ574148A (es)
PE (1) PE20081003A1 (es)
PL (2) PL2351554T3 (es)
PT (2) PT2040672E (es)
RU (1) RU2468787C2 (es)
SG (2) SG173354A1 (es)
TW (1) TW200812640A (es)
UY (1) UY30484A1 (es)
WO (1) WO2008008364A2 (es)
ZA (1) ZA200900315B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
TWI405567B (zh) * 2006-06-01 2013-08-21 Merck Sharp & Dohme 持續釋放脫羥腎上腺素之醫藥組合物
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
PL2034970T3 (pl) * 2006-06-01 2012-12-31 Msd Consumer Care Inc Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę
CN101472561A (zh) * 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物
US20080299186A1 (en) * 2007-06-01 2008-12-04 Schering-Plough Healthcare Products, Inc. Coatings for applying substances onto substrate carrier
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US8518439B2 (en) * 2008-12-03 2013-08-27 Novartis Ag Liquid therapeutic composition
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
WO2011156822A2 (en) * 2010-06-11 2011-12-15 Gm Pharmaceuticals, Inc. Pharmaceutical compositions
SI2616064T1 (sl) 2010-10-21 2019-12-31 Rtu Pharmaceuticals Llc Pripravki ketorolaka, pripravljeni za uporabo
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
AU2014222418B2 (en) * 2013-02-28 2016-06-23 Pf Consumer Healthcare 1 Llc Enhanced stability of novel liquid compositions
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
JP5918895B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
RU2017145602A (ru) * 2015-05-29 2019-07-02 Кил Лэборетериз, Инк. Жидкие композиции целекоксиба для перорального введения
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
MX2019002334A (es) * 2016-09-01 2019-05-16 Procter & Gamble Medicamentos con sabor y experiencia sensorial mejorados.
MX2019003039A (es) 2016-09-26 2019-07-08 Procter & Gamble Forma de dosificacion de alivio prolongado.
CN110115708A (zh) * 2018-02-07 2019-08-13 保瑞药业股份有限公司 乙酰胺酚及曲马多共溶复方止痛口服液
EP3793535A1 (en) 2018-05-16 2021-03-24 Bayer Healthcare LLC High concentration suspension formulation for cold and flu soft gel capsule medications
CN108434097A (zh) * 2018-06-22 2018-08-24 南京济群医药科技股份有限公司 一种稳定的含盐酸曲普利啶口服溶液剂及其制备方法
CN109010341A (zh) * 2018-10-29 2018-12-18 南京济群医药科技股份有限公司 一种含有氢溴酸右美沙芬的复方口服溶液及其制备方法
SG11202110546UA (en) 2019-04-11 2021-10-28 R P Scherer Technologies Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
RS65089B1 (sr) 2019-12-23 2024-02-29 Nutra Essential Otc S L Tečna kompozicija koja sadrži ibuprofen i fenilefrin
US20210228507A1 (en) * 2020-01-22 2021-07-29 Nevakar Inc. Phenylephrine Hydrochloride Compositions and Containers
CN111773203A (zh) * 2020-05-15 2020-10-16 北京博达绿洲医药科技研究有限公司 一种包含盐酸去氧肾上腺素组合物的制备工艺
CN114533664B (zh) * 2022-01-29 2023-03-31 江苏广承药业有限公司 一种氢溴酸右美沙芬和愈创木酚甘油醚复方口服液体制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515781A (en) * 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US6287597B1 (en) 1999-03-12 2001-09-11 Carter-Wallace, Inc. Antihistaminic/decongestant compositions
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
EP1411955A4 (en) 2001-07-31 2006-07-05 Wyeth Corp SUCRALOSE FORMULATIONS FOR COVERING UNANGEAN TASTE
US6462094B1 (en) * 2001-08-22 2002-10-08 Medpointe Healthcare Inc. Decongestant/expectorant compositions
US6509492B1 (en) * 2001-08-31 2003-01-21 First Horizon Pharmaceutical Corporation Tannate compositions and methods of treatment
US20030060422A1 (en) * 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US20040132827A1 (en) 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
EP1559433A4 (en) * 2002-10-22 2009-11-04 Dainippon Sumitomo Pharma Co STABILIZED COMPOSITION
US6979689B2 (en) 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
JP2004300138A (ja) * 2003-03-18 2004-10-28 Takeda Chem Ind Ltd 安定化された経口固形製剤
US20050152967A1 (en) 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
DE10358213A1 (de) * 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20060148837A1 (en) 2005-01-04 2006-07-06 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
US20070160689A1 (en) * 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness

Also Published As

Publication number Publication date
EP2040672B1 (en) 2015-04-01
BRPI0714399B8 (pt) 2021-05-25
HUE025694T2 (hu) 2016-04-28
HK1205933A1 (en) 2015-12-31
WO2008008364A3 (en) 2008-05-22
ES2550036T3 (es) 2015-11-04
ES2537761T3 (es) 2015-06-11
IL196447A (en) 2015-06-30
AU2007272961B2 (en) 2011-07-28
US20080014274A1 (en) 2008-01-17
EP2040672A2 (en) 2009-04-01
TW200812640A (en) 2008-03-16
WO2008008364A2 (en) 2008-01-17
PE20081003A1 (es) 2008-07-13
PT2040672E (pt) 2015-07-02
PT2351554E (pt) 2015-11-02
PL2351554T3 (pl) 2016-01-29
SG173354A1 (en) 2011-08-29
JP2009543777A (ja) 2009-12-10
IL196447A0 (en) 2009-09-22
RU2009101295A (ru) 2010-08-27
HK1128886A1 (en) 2009-11-13
HUE025790T2 (hu) 2016-05-30
CA2657611A1 (en) 2008-01-17
UY30484A1 (es) 2008-02-29
ZA200900315B (en) 2009-12-30
BRPI0714399A2 (pt) 2013-03-12
PL2040672T3 (pl) 2015-07-31
SG10201408522UA (en) 2015-02-27
EP2351554A1 (en) 2011-08-03
CN101500539A (zh) 2009-08-05
MX2009000530A (es) 2009-01-27
EP2351554B1 (en) 2015-09-09
AU2007272961A1 (en) 2008-01-17
KR20090040334A (ko) 2009-04-23
AR061985A1 (es) 2008-08-10
ECSP099072A (es) 2009-02-27
KR20140088234A (ko) 2014-07-09
BRPI0714399B1 (pt) 2020-11-17
CN104546671A (zh) 2015-04-29
NZ574148A (en) 2012-07-27
RU2468787C2 (ru) 2012-12-10

Similar Documents

Publication Publication Date Title
CO6180496A2 (es) Composiciones liquidas de fenilefrina de estabilidad mejorada
CO6180502A2 (es) Comprimido masticable que contiene fenilefrina
JP2009543777A5 (es)
JP2009544699A5 (es)
Ward et al. Paracetamol revisited: a review of the pharmacokinetics and pharmacodynamics
Miranda et al. Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain
TWI482620B (zh) 脫羥腎上腺素液體調配物
Tallarida et al. Antinociceptive synergy, additivity, and subadditivity with combinations of oral glucosamine plus nonopioid analgesics in mice
Bonabello et al. Dexibuprofen (S (+)-isomer ibuprofen) reduces gastric damage and improves analgesic and antiinflammatory effects in rodents
JP2010090142A5 (es)
UY27575A1 (es) Soluciones de metolixicam estables y muy concentradas para la inyección sin aguja
PE20100149A1 (es) Composiciones farmaceuticas a base de agonistas del receptor s1p
CA2459757A1 (en) Combination
RU2009139260A (ru) Таблетка с улучшенной стабильностью, содержащая по меньшей мере два активных компонента
UY32299A (es) Composiciones farmacéuticas líquidas
PE20081072A1 (es) Composiciones de anti-histaminicos, descongestivos, antitusivos y drogas anti-inflamatorios no esteroidales
DOP2006000018A (es) Formulaciones y regimen de dosificación para moduladores alfa de ppar
CL2012001324A1 (es) Proceso para la preparacion de formulaciones solidas de sales de amina de los acidos carboxilicos que contienen piridina herbicida, donde se utiliza menos de un equivalente molar de la amina con respecto a los ácidos carboxilicos que contienen piridina herbicida.
Zhang et al. Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma
Isiordia‐Espinoza et al. Synergism between tramadol and meloxicam in the formalin test involves both opioidergic and serotonergic pathways
AR003470A1 (es) Composicion para proporcionar tratamiento o atenuacion mejorados de sintomas de resfrio, alergia, sinusitis o gripe compuesta por un activoanalgesico y un agente antihistaminico de ester de pirrilidona o piperidina
Brune et al. Towards safer nonsteroidal anti-inflammatory drugs.
Dawson et al. Derivation of a Retinoid X Receptor Scaffold from Peroxisome Proliferator‐Activated Receptor γ Ligand 1‐Di (1H‐indol‐3‐yl) methyl‐4‐trifluoromethylbenzene
ITMI20040235A1 (it) Preparazione farmaceutica per il cavo orale
Bhat et al. The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study

Legal Events

Date Code Title Description
FC Application refused